Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfosulfuron SCHEMBL66574 | 0.86 | GAA (0.49) | GAAMAPTTP53GLACDK1 | |
| Sulfosulfuron SCHEMBL8476425 | 0.83 | GAA (0.46) | GAAMAPTTP53GLACDK1 | |
| SCHEMBL8461112 | 0.77 | CDK2 (0.40) | GAAMAPTTP53GLACDK1 | |
| Sulfosulfuron SCHEMBL2431369 | 0.75 | PKM (0.39) | GAAMAPTTP53GLAKMT2A | |
| Sulfosulfuron SCHEMBL14655298 | 0.75 | GAA (0.38) | GAAMAPTTP53GLACDK1 | |
| SCHEMBL8477231 | 0.75 | GAA (0.52) | GAAMAPTTP53GLACDK1 | |
| SCHEMBL7189218 | 0.75 | FBP1 (0.39) | GAAMAPTTP53GLAKMT2A | |
| SCHEMBL8475296 | 0.75 | GAA (0.48) | GAAMAPTTP53GLACDK1 | |
| Sulfosulfuron SCHEMBL14655515 | 0.75 | GAA (0.39) | GAAMAPTTP53GLACDK1 | |
| Sulfosulfuron SCHEMBL9938892 | 0.75 | CDK1 (0.39) | GAAMAPTTP53GLACDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050233908-A1 | Use of sulfonylureas | BAYER CORPSCIENCE GMBH (DE) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050233908-A1 | Use of sulfonylureas | CBR3, MRPL11, AGL | GAA 1930/4885MAPT 4862/4885TP53 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.